Celularity Inc (CELUW)

Annual Report Filed: 2026-04-30

Key Insights

The filing content appears to be incomplete XML/XBRL data structure without actual financial statements, making it impossible to assess revenue trends, profitability metrics, or operational performance for fiscal year 2025.
Multiple debt instruments are evident including convertible promissory notes, senior convertible notes, and various warrant classes (Yorkville, KTL, Sponsors), indicating significant leverage and potential dilution concerns for shareholders.
Customer concentration risk is noted with only 2-3 major customers representing material revenue in 2025, creating vulnerability to customer loss or contract changes that could materially impact financial results.
The filing references a Sequence Life Science Inc acquisition completed October 9, 2024, but lacks detail on acquisition terms, integration progress, or synergy realization critical for evaluating strategic value.

Current Report Filed: 2026-04-21

Key Insights

Material agreement with NexGel for $13.3 million in consideration ($8.3M upfront + $5M convertible note) includes milestone payment of $2.5M contingent on achieving $25M net sales within 15 months, indicating continued execution risk on the divested biomaterials business.
Helena Global Investment triggered a notice of default on $1.97M convertible promissory note citing the Company's failure to timely file its 2025 Form 10-K; Helena can demand 115% of outstanding principal if not cured within 5 business days, creating immediate liquidity pressure and regulatory compliance concerns.
Multiple leadership departures in April 2026 (Senior VP John Haines terminated, President Stephen Brigido resigned) as part of strategic realignment raise questions about organizational stability during the critical biomaterials divestiture transition.
The termination of the product purchase credit in the NexGel amendment and extension of outside closing date to April 30, 2026 suggests potential transaction execution challenges and reduced financial flexibility from the original agreement structure.

Insider Trading Filed: 2026-04-15

Key Insights

The reporting person, Robert J. Hariri, exercised 3,281 restricted stock units (RSUs) that vested on 04/13/2026, indicating ongoing equity ownership in the company.
Hariri, who serves as the Chief Executive Officer and a Director, disposed of 1,182 shares to cover tax withholding obligations, suggesting he continues to hold a significant stake in Celularity Inc.
The reported transactions suggest alignment between Hariri's interests and those of other shareholders, as he maintains a substantial direct ownership position in the company.

Insider Trading Filed: 2026-04-15

Key Insights

The reporting person, John Haines, who is the Senior Exec Vice President of Celularity Inc., has exercised 1,641 restricted stock units (RSUs) into Class A common stock of the company.
Haines has also sold 583 shares to cover tax withholding obligations related to the vesting of the RSUs, indicating ongoing insider activity.
The reporting of this insider transaction provides transparency into Haines' ownership and the company's equity compensation practices.

Insider Trading Filed: 2026-04-15

Key Insights

The reporting person, Stephen Brigido, is an officer (President, Functional Regeneration) of Celularity Inc. and holds a direct ownership position in the company's Class A common stock.
Brigido exercised 821 restricted stock units (RSUs) on April 13, 2026, and 268 shares were withheld for tax purposes, leaving him with a direct ownership of 9,474 shares of Class A common stock.
The vesting of the RSUs appears to be part of Brigido's executive compensation and aligns his interests with those of the company and its shareholders.

Current Report Filed: 2026-03-10

Key Insights

Celularity Inc. has entered into an asset purchase and exclusive license agreement with NexGel, Inc. to sell its commercial-stage biomaterials portfolio and certain development-stage programs for up to $35 million.
The agreement includes a $15 million upfront payment and an additional $20 million in potential milestone payments based on net sales targets.
The transaction is subject to customary conditions, including NexGel's receipt of sufficient financing to pay the initial upfront payment.

Current Report Filed: 2026-03-05

Key Insights

Joseph DosSantos, the SVP and Acting Chief Financial Officer, has left the company for personal reasons.
John Sprague has been appointed as the new Acting Chief Financial Officer, indicating a change in the company's leadership.
The company is an emerging growth company and has not elected to use the extended transition period for complying with new or revised financial accounting standards.

Insider Trading Filed: 2026-01-14

Key Insights

The reporting person, Diane L. Parks, has been granted 30,000 restricted stock units (RSUs) under the Celularity Inc. 2021 Equity Incentive Plan. These RSUs will vest on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting, subject to her continuous service with the company.
The reporting person's total beneficial ownership of Celularity Inc. Class A common stock has increased to 520,021 shares following this RSU grant.
This RSU grant to a director suggests Celularity Inc. is providing equity-based compensation to its board members, which is a common practice to align their interests with those of shareholders.

Insider Trading Filed: 2026-01-14

Key Insights

Celularity Inc. director Peter Diamandis acquired 20,385 restricted stock units (RSUs) on January 12, 2026, representing a direct ownership interest in the company.
The RSUs vest on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting, subject to Diamandis' continued service with Celularity.
This acquisition of equity by a director suggests ongoing commitment and alignment of interests between Diamandis and Celularity shareholders.

Insider Trading Filed: 2026-01-14

Key Insights

The reporting person, Vincent LeVien, has been granted 28,847 restricted stock units (RSUs) under the Celularity Inc. 2021 Equity Incentive Plan, which will vest on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting.
The total number of Class A common stock beneficially owned by the reporting person following this transaction is 153,847 shares.
This transaction represents an insider grant of equity-based compensation, which could indicate the company's confidence in the reporting person and their role within the organization.

Insider Trading Filed: 2026-01-14

Key Insights

Geoffrey Ling, a director of Celularity Inc., was granted 19,231 restricted stock units (RSUs) on January 12, 2026, which will vest over one year or by the next annual shareholder meeting.
The RSUs granted to Ling represent a direct ownership position in the company, aligning his interests with those of other shareholders.
This transaction suggests continued confidence in Celularity's prospects by an insider with a significant role in the company's governance and strategic direction.

Insider Trading Filed: 2025-12-30

Key Insights

The reporting person, Peter Diamandis, acquired 125,000 restricted stock units (RSUs) in Celularity Inc. (CELUW) on December 29, 2025, with the RSUs vesting on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting.
Diamandis also received a stock option grant of 156,250 shares, with the same vesting schedule as the RSUs, further aligning his interests with the company.
The insider transactions suggest Diamandis, who serves as a director, has a positive view of Celularity's future prospects and is willing to increase his equity stake in the company.

Insider Trading Filed: 2025-12-30

Key Insights

Diane L. Parks, a director of Celularity Inc., acquired 125,000 restricted stock units (RSUs) and 156,250 stock options on December 29, 2025, indicating her continued investment and confidence in the company.
The RSUs and stock options granted to Diane L. Parks will vest and become exercisable on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting, subject to her continuous service with the company.
The acquisition of a significant number of equity securities by a director suggests potential alignment between management and shareholders, which may be a positive signal for the company's future prospects.

Insider Trading Filed: 2025-12-30

Key Insights

Geoffrey Ling, a director of Celularity Inc., acquired 125,000 shares of Class A common stock through restricted stock units (RSUs) granted under the company's 2021 Equity Incentive Plan.
The RSUs vest and become exercisable on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting, subject to Ling's continuous service with the company.
Ling also received a stock option grant of 156,250 shares of Class A common stock, which also vest on the earlier of the one-year anniversary or the next annual meeting, subject to his continued service.

Insider Trading Filed: 2025-12-30

Key Insights

The reporting person, Vincent LeVien, was granted 125,000 restricted stock units (RSUs) of Celularity Inc. (CELUW) on December 29, 2025, vesting on the earlier of one year from the grant date or the next annual stockholder meeting.
LeVien was also granted 156,250 stock options with an exercise price of $1.2, vesting on the same schedule as the RSUs.
This insider ownership grant suggests the company is incentivizing its leadership to drive long-term value creation for shareholders.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information